| Parameter | Specification | | :--- | :--- | | | CT-P44 | | Input Voltage | 100-240 VAC, 50/60 Hz | | Output Voltage | 48 VDC (Adjustable 42-58V) | | Max Current | 90A | | Efficiency | ≥ 94% | | Cooling Method | Forced Air (Smart Fan) | | Dimensions | 450mm x 220mm x 150mm | | Weight | 7.2 kg (15.8 lbs) | | Operating Temp | -20°C to +50°C |
Based on the alphanumeric code "," which strongly resembles a technical product code (likely for a Charge Tank , Power Supply , or Industrial Component ), the following content package has been assembled. ct-p44
is an investigational drug candidate developed by Celltrion . Based on publicly available information: | Parameter | Specification | | :--- |
If you meant a different (e.g., from another company or a non-pharma context), please provide more details (e.g., subject area, authors, or journal). I’d be happy to help you locate the exact paper. I’d be happy to help you locate the exact paper
, targeting a market where patents for the original drug are set to expire in 2029 and 2031. The clinical trial, known under the identifier NCT06952478 , was designed to test CT-P44 as a subcutaneous (SC) injection in combination with other therapies over a two-year period. The Patient at the Center Imagine a patient in a relapsed state, someone for whom traditional therapies have failed. For them, CT-P44 represents more than just a "biosimilar candidate." It is a promise of